CVS agrees to $315M settlement in DOJ opioid epidemic lawsuit
A 2024 lawsuit against CVS Health has come to an end, with the healthcare company coming to a settlement agreement with the U.S. Department of Justice (DOJ), whereby it will pay $315 million to resolve allegations that it violated the Controlled Substances Act and the False Claims Act.
CVS, through its network of retail pharmacy outlets, was formally sued by the DOJ in December 2024, with authorities claiming it pressured staff to fill prescriptions for opioids that “lacked a legitimate medical purpose,” going on to then bill federal healthcare programs for the “unlawful prescriptions.”
The initial complaint was made by whistleblower Hillary Estright, who previously worked for CVS and filed an action in 2019 under qui tam provisions of the False Claims Act, which allows a private party to sue on behalf of the U.S. government, which can then later intervene and take over legal complaints found to have merit.
Despite agreeing to pay $315 million, CVS Health does not admit to any wrongdoing and the claims against the company remain allegations only, the DOJ said in a statement released Tuesday. All the same, the agency framed the settlement as a victory for those combating the opioid epidemic.
“Not only does this settlement hold bad actors accountable for their fraudulent activities, but Americans are safer because of it,” said Associate Attorney General Stanley E. Woodward Jr. “Today’s settlement is a significant milestone in the Justice Department’s efforts to combat the opioid epidemic by cracking down on pharmacies that unlawfully fulfill prescriptions for controlled substances.”
It was alleged in the complaint that unlawful activity at CVS pharmacies included the routine filling of prescriptions from known “pill mills,” where prescribers had been flagged for potential illegal activity regarding the distribution of controlled substances.
Further, CVS would allegedly pressure its pharmacists to fill prescriptions for opioids and other controlled substances in “dangerous and excessive” amounts, including incidents where patients were prescribed a dangerous combination of benzodiazepine and painkillers, which the DOJ referred to as a “trinity.”
The complaint alleged that CVS created this culture of the over-filling of prescriptions—and subsequent submissions for reimbursement—by offering staff incentive compensation based on performance metrics that prioritized “corporate profits over patient safety,” the DOJ added.
Complaint looks back over a decade
Incidents in which CVS pharmacies allegedly overfilled prescriptions for opioids and sought reimbursement from Medicare began as early as 2013, and they did not stop in 2019 when the whistleblower made the initial complaint, nor in 2024 when the DOJ took over the lawsuit.
Instead, authorities allege CVS engaged in this unlawful conduct until December 2025.
However, as part of the settlement, the company has agreed to put new safeguards in place to monitor prescription activity and prevent future incidents where controlled substances are possibly released to patients who will abuse or sell the medication.
The company also released a statement to multiple media outlets refuting allegations made by the DOJ, reiterating that a settlement agreement is not an admission of guilt.
“We’ve implemented best-in-class and first-of-their-kind programs to help our pharmacists make the best decisions on behalf of patients," a spokesperson said. “We’re pleased to move forward and put this litigation behind us.”
This isn’t the first time the pharmacy chain has been accused of contributing to the opioid crisis. In 2024, CVS agreed to a $45 million settlement with the city of Baltimore, which had accused multiple pharmacy chains of carelessly filling prescriptions for controlled substances, namely addictive painkillers.
Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.